1. A data processing method comprising:
generating at a subscriber terminal a service request, the service request including a service identifier and a unique identifier of the subscriber terminal;
providing the service request to a validation entity;
receiving a decryption code from the validation entity in response to the service request, the decryption code being based on the unique identifier and an encryption key;
receiving an encrypted data service at the subscriber terminal, the encrypted data service being associated with the service identifier and being encrypted using the encryption key; and
processing the encrypted data service using the decryption code to generate decrypted data.
2. The method of claim 1, wherein the encrypted data service is a subscription-based service received from a service provider remote from the subscriber terminal.
3. The method of claim 2, wherein the subscription-based service is a cable television service.
4. The method of claim 2, wherein the subscription-based service is a satellite television service.
5. The method of claim 3, wherein the service identifier includes a channel identifier corresponding to a television channel of the subscription-based service.
6. The method of claim 4, wherein the service identifier includes a channel identifier corresponding to a television channel of the subscription-based service.
7. The method of claim 1, wherein the processing includes performing a first logic operation on the encrypted data service using a first logic function and the unique identifier to generate partially decrypted data.
8. The method of claim 7, wherein the processing further includes performing a second logic operation on the partially decrypted data using a second logic function and the decryption code.
9. The method of claim 1, wherein the decryption code includes a decryption key and format information.
10. The method of claim 9, wherein the format information includes the service identifier.
11. The method of claim 9, wherein the format information includes a validation code for validating the decryption code.
12. The method of claim 9, wherein the format information includes a format code, the format code specifying one or more logic functions to be used in the processing.
13. The method of claim 12, wherein the format code specifies whether a variable decryption key is to be used in the processing and, if the variable decryption key is to be used, the format information includes a seed value for generating the variable decryption key.
14. The method of claim 8, wherein performing the second logic operation generates further partially decrypted data and the processing further includes performing a third logic operation on the further partially decrypted data using a third logic function and a variable decryption key generated based on the decryption code.
15. The method of claim 14, wherein the variable decryption key comprises a number sequence generated based on a seed value specified in the decryption code.
16. The method of claim 15, wherein the number sequence is a pseudo-random number sequence.
17. The method of claim 16, wherein the pseudo-random number sequence is generated by a linear feedback shift register circuit.
18. A method of providing a service, comprising:
receiving at a validation entity a service request for an encrypted data service, the service request including a service identifier and a unique identifier of a subscriber terminal;
generating a decryption code in response to the service request based on an encryption code and the unique identifier;
providing the decryption code to the subscriber terminal;
encrypting a data service corresponding to the service identifier using the encryption code; and
transmitting the encrypted data service to the subscriber terminal for decryption of the encrypted data service by the subscriber terminal using the decryption code.
19. The method of claim 18, wherein the encrypted data service is a subscription-based service.
20. The method of claim 19, wherein the subscription-based service is a cable television service.
21. The method of claim 19, wherein the subscription-based service is a satellite television service.
22. The method of claim 18, wherein the service request is received from the subscriber terminal.
23. The method of claim 18, wherein the providing includes transmitting the decryption code to the subscriber terminal over a transmission medium specific to the data service.
24. The method of claim 18, wherein the providing includes transmitting the decryption code to the subscriber terminal over a network.
25. The method of claim 18, further comprising, prior to the step of generating, the step of validating the service request.
26. The method of claim 25, wherein the step of validating includes checking the service request against a subscriber account status.
27. The method of claim 18, wherein the encrypted data service includes one or more channels.
28. The method of claim 27, wherein the service identifier comprises one or more channel identifiers.
29. The method of claim 18, wherein the decryption code includes a decryption key and format information.
30. The method of claim 29, wherein the format information includes the service identifier.
31. The method of claim 29, wherein the format information includes a validation code for validating the decryption code.
32. The method of claim 29, wherein the format information includes a format code, the format code specifying one or more logic functions to be used in the decryption.
33. The method of claim 32, wherein the format code specifies whether a variable decryption key is to be used in the decryption and, if the variable decryption key is to be used, the format information includes a seed value for generating the variable decryption key.
34. The method of claim 18, wherein the encrypted data service includes a radio service.
35. A data processing device for an encrypted data service, the device comprising:
a processor for receiving and processing an encrypted data service from a service provider, the processor being configured to determine a first unique identifier of the encrypted data service; and
a memory storing a decryption code corresponding to the first unique identifier and a second unique identifier of the data processing device;
wherein the processor is configured to decrypt the encrypted data service based on the decryption code and the second unique identifier.
36. The device of claim 35, further comprising means for communicating with a code provider associated with the service provider to receive the decryption code for the encrypted data service.
37. The device of claim 35, wherein the decryption code includes a decryption key and format information and wherein the processor is configured to determine a decryption format of the encrypted data service based on the format information and to decrypt the encrypted data service based on the decryption key, the decryption format and the second unique identifier.
38. The device of claim 35, wherein the encrypted data service forms part of a television service.
39. The device of claim 38, wherein the encrypted data service comprises a cable television channel.
40. The device of claim 38, wherein the encrypted data service comprises a satellite television channel.
41. The device of claim 38, wherein the encrypted data service comprises a video-on-demand service.
42. The device of claim 38, wherein the encrypted data service comprises a pay-per-view service.
43. The device of claim 37, wherein the format information includes the first unique identifier.
44. The device of claim 37, wherein the format information includes a validation code for validating the decryption code.
45. The device of claim 37, wherein the format information includes a format code, the format code specifying one or more logic functions to be used in the decryption.
46. The device of claim 37, wherein the format code specifies whether a variable decryption key is to be used in the decryption and, if the variable decryption key is to be used, the format information includes a seed value for generating the variable decryption key.
47. The device of claim 35, wherein the first unique identifier includes a channel identifier corresponding to a television channel of the encrypted data service.
48. The device of claim 35, wherein the processor is configured to perform a first logic operation on the encrypted data service using a first logic function and the second unique identifier to generate partially decrypted data.
49. The device of claim 48, wherein the processor is further configured to perform a second logic operation on the partially decrypted data using a second logic function and the decryption code.
50. The device of claim 49, wherein the output of the second logic operation is further partially decrypted data and the processor is further configured to perform a third logic operation on the further partially decrypted data using a third logic function and a variable decryption key.
51. The device of claim 50, wherein the processor is configured to determine the variable decryption key based on the decryption code.
52. The device of claim 51, wherein the variable decryption key comprises a number sequence generated based on a seed value specified in the decryption code.
53. The device of claim 52, wherein the number sequence is a pseudo-random number sequence.
54. The device of claim 53, further comprising a linear feedback shift register (LFSR) circuit, wherein the pseudo-random number sequence is generated by the LFSR circuit.
55. The device of claim 35, wherein the encrypted data service includes a radio service.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A pyrazolopyrimidine compound represented by the formula I:
wherein
R1 represents a C1-6 alkyl group, a C3-8 cycloalkyl group, a C2-9 heterocyclyl group, a C1-9 heteroaryl group or a phenyl group (wherein the C1-6 alkyl group, the C3-8 cycloalkyl group, the C2-9 heterocyclyl group, the C1-9 heteroaryl group and the phenyl group are unsubstituted or substituted with 1 to 4 substituents selected from the following Substituent Group A1);
Substituent Group A\u2032 represents
a group consisting of a halogen atom, a hydroxy group, an amino group, a cyano group, a carboxy group, a C1-6 alkyl group, a trifluoromethyl group, a C3-8 cycloalkyl group, a C1-6 alkoxy group (wherein the C1-6 alkoxy group is unsubstituted or substituted with a hydroxy group), a sulfanyl group, a C1-6 alkylsulfanyl group, a C1-6 alkoxycarbonyl group, a C3-8 cycloalkoxy group, a (C1-6 alkyl)amino group, a di(C1-6 alkyl)amino group, a C1-6 alkoxycarbonylamino group, a hydroxyaminocarbonyl group, a ureido group, a carbamoyl group, a C2-9 heterocyclyl group (wherein the C2-9 heterocyclyl group is unsubstituted or substituted with a C1-6 alkyl group or an oxo group), a C1-9 heteroaryl group, a (C1-6 acyl)amino group and an oxo group;
R2 represents a C1-6 alkyl group;
n represents an integer of 0, 1 or 2;
Y represents \u2014O\u2014 or \u2014NR3\u2014 (wherein R3 represents a hydrogen atom or a C1-6 alkyl group);
Ar represents a C1-9 heteroaryl group (wherein the C1-9 heteroaryl group is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of a sulfanyl group, a hydroxy group, a C1-6 alkoxy group, a morpholinyl group, a trifluoromethyl group and an oxo group) or a phenyl group (wherein the phenyl group is unsubstituted or substituted with the same or different 1 to 3 Ras); and
Ra represents a hydroxy group, a cyano group, a carboxy group, a sulfanyl group, a C1-6 alkoxycarbonyl group, a C1-6 alkyl group (wherein the C1-6 alkyl group is unsubstituted or substituted with a carboxy group or -CONR4R5 (wherein R4 and R5 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group)), a C3-8 cycloalkyl group, a C1-6 alkoxy group (wherein the C1-6 alkoxy group is unsubstituted or substituted with a carboxy group or \u2014CONR6R7 (wherein R6 and R7 are the same or different and each represent a hydrogen atom, a C1-6 alkyl group, a C3-8 cycloalkyl group, a C1-6 alkoxy group, a C2-9 heterocyclyl group or a C1-9 heteroaryl group)), a C1-9 heteroaryl group, a C3-8 cycloalkoxy group, a halogen atom, a trifluoromethyl group, a trifluoromethoxy group, a phenoxy group, a phenyl group (wherein the phenyl group is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of a carboxy group, a C1-6 alkoxycarbonyl group and \u2014SO2NR14R15 (wherein R14 and R15 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group)), \u2014NR8R9, \u2014CONR8R9, \u2014NR8SO2R9 or \u2014SO2NR8R9 (wherein R8 and R9 are the same or different and each represent a hydrogen atom, a C1-6 acyl group, a C1-6 alkoxycarbonyl group, a toluyl group, a naphthyl group, a C1-9 heteroaryl group or a C1-6 alkyl group (wherein the C1-6 alkyl group is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of a hydroxy group, a carboxy group and a C1-6 alkoxy group),
or when R8 and R9 are substituents on the adjacent nitrogen atom, they, together with the adjacent nitrogen atom, represent the formula II:
wherein Q represents \u2014O\u2014, \u2014NR10\u2014, \u2014CHR11\u2014, \u2014CO\u2014 (wherein the \u2014CO\u2014 is unprotected or protected with ethylene ketal), \u2014S\u2014, \u2014SO\u2014 or \u2014SO2\u2014;
L1 and L2 are the same or different and each represent a linear C1-3 alkylene group (wherein the linear C1-3 alkylene group is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of a C1-6 alkyl group and an oxo group);
R10 represents a hydrogen atom, a C1-6 acyl group, a C1-6 alkyl group, a C1-6 alkylsulfonyl group, a trifluoromethylsulfonyl group, a phenylcarbonyl group or a phenylsulfonyl group (wherein the phenylcarbonyl group and the phenylsulfonyl group are unsubstituted or substituted with 1 to 2 substituents selected from Substituent Group B);
Substituent Group B represents a group consisting of a halogen atom, a C1-6 alkyl group and a C1-6 alkoxy group; and
R11 represents a hydrogen atom, a hydroxy group, a C1-6 alkyl group (wherein the C1-6 alkyl group is unsubstituted or substituted with a C1-6 alkoxy group or a hydroxy group), a C1-6 alkoxy group, a carboxy group, an amino group, a (C1-6 alkyl)amino group, a di(C1-6 alkyl)amino group, a (C1-6 acyl)amino group, a phenylcarbonyl group, \u2014CONR12R13 (wherein R12 and R13 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group, or they, together with the adjacent nitrogen atom, represent a C2-9 heterocyclyl group) or a (C1-6 alkylsulfonyl)amino group);
a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
2. The pyrazolopyrimidine compound, a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof, according to claim 1, wherein R1 is a C1-6 alkyl group, a C3-8 cycloalkyl group or a C2-9 heterocyclyl group (wherein the C1-6 alkyl group, the C3-8 cycloalkyl group and the C2-9 heterocyclyl group are unsubstituted or substituted with 1 to 4 substituents selected from the following Substituent Group A);
Substituent Group A represents
a group consisting of a halogen atom, a hydroxy group, an amino group, a cyano group, a carboxy group, a C1-6 alkyl group, a C3-8 cycloalkyl group, a C1-6 alkoxy group (wherein the C1-6 alkoxy group is unsubstituted or substituted with a hydroxy group), a C1-6 alkylsulfanyl group, a C1-6 alkoxycarbonyl group, a C3-8 cycloalkoxy group, a (C1-6 alkyl)amino group, a di(C1-6 alkyl)amino group, a C1-6 alkoxycarbonylamino group, a hydroxyaminocarbonyl group, a ureido group, a carbamoyl group, a C2-9 heterocyclyl group (wherein the C2-9 heterocyclyl group is unsubstituted or substituted with a C1-6 alkyl group or an oxo group) and a C1-9 heteroaryl group;
R2 is a linear C1-6 alkyl group;
Ar is a C1-9 heteroaryl group (wherein the C1-9 heteroaryl group is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of a sulfanyl group, a hydroxy group, a C1-6 alkoxy group, a morpholinyl group and a trifluoromethyl group) or a phenyl group (wherein the phenyl group is unsubstituted or substituted with the same or different 1 to 3 Ras); and
Ra is a hydroxy group, a cyano group, a carboxy group, a sulfanyl group, a C1-6 alkoxycarbonyl group, a C1-6 alkyl group (wherein the C1-6 alkyl group is unsubstituted or substituted with a carboxy group or \u2014CONR4R5 (wherein R4 and R5 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group)), a C3-8 cycloalkyl group, a C1-6 alkoxy group (wherein the C1-6 alkoxy group is unsubstituted or substituted with a carboxy group or \u2014CONR6R7 (wherein R6 and R7 are the same or different and each represent a hydrogen atom, a C1-6 alkyl group, a C3-8 cycloalkyl group, a C1-6 alkoxy group, a C2-9 heterocyclyl group or a C1-9 heteroaryl group)), a C 1-9 heteroaryl group, a C3-8 cycloalkoxy group, a halogen atom, a trifluoromethyl group, a trifluoromethoxy group, a phenoxy group, \u2014NR8R9, \u2014CONR8R9, \u2014NR8SO2R9 or \u2014SO2NR8R9 (wherein R8 and R9 are the same or different and each represent a hydrogen atom, a C1-6 acyl group, a C1-6 alkoxycarbonyl group, a toluyl group, a C1-9 heteroaryl group or a C1-6 alkyl group (wherein the C1-6 alkyl group is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of a hydroxy group, a carboxy group and a C1-6 alkoxy group),
or when R8 and R9 are substituents on the adjacent nitrogen atom, they, together with the adjacent nitrogen atom, represent the formula II:
wherein Q represents \u2014O\u2014, \u2014NR10\u2014, \u2014CHR11\u2014, \u2014CO\u2014 (wherein the \u2014CO\u2014 is unprotected or protected with ethylene ketal), \u2014S\u2014, \u2014SO\u2014 or \u2014SO2\u2014;
L1 and L2 are the same or different and each represent a linear C1-3 alkylene group (wherein the linear C1-3 alkylene group is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of a C1-6 alkyl group and an oxo group);
R10 represents a hydrogen atom, a C1-6 acyl group, a C1-6 alkyl group, a C1-6 alkylsulfonyl group, a trifluoromethylsulfonyl group, a phenylcarbonyl group or a phenylsulfonyl group (wherein the phenylcarbonyl group and the phenylsulfonyl group are unsubstituted or substituted with 1 to 2 substituents selected from Substituent Group B);
Substituent Group B represents a group consisting of a halogen atom, a C1-6 alkyl group and a C1-6 alkoxy group; and
R11 represents a hydrogen atom, a hydroxy group, a C1-6 alkyl group (wherein the C1-6 alkyl group is unsubstituted or substituted with a C1-6 alkoxy group or a hydroxy group), a C1-6 alkoxy group, a carboxy group, an amino group, a (C1-6 alkyl)amino group, a di(C1-6 alkyl)amino group, a (C1-6 acyl)amino group, a phenylcarbonyl group, \u2014CONR12R13 (wherein R12 and R13 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group, or they, together with the adjacent nitrogen atom, represent a C2-9 heterocyclyl group) or a (C1-6 alkylsulfonyl)amino group).
3. The pyrazolopyrimidine compound, a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 2, wherein Ar is a phenyl group (wherein the phenyl group is unsubstituted or substituted with the same or different 1 to 3 Ras).
4. The pyrazolopyrimidine compound, a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 2, wherein Ar is a phenyl group (wherein the phenyl group is substituted at the 3-, 4- or 5-position with the same or different 1 to 3 Ras).
5. The pyrazolopyrimidine compound, a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 2 to 4, wherein Y is NH.
6. The pyrazolopyrimidine compound, a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 2 to 4, wherein R1 is a C1-8 alkyl group (wherein the C1-8 alkyl group is unsubstituted or substituted with an amino group, a (C1-6 alkyl)amino group or a di(C1-6 alkyl)amino group).
7. The pyrazolopyrimidine compound, a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of claims 2 to 4, wherein R1 is a C3-8 cycloalkyl group (wherein the C3-8 cycloalkyl group is unsubstituted or substituted with an amino group).
8. The pyrazolopyrimidine compound, a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 1, wherein R1 is a C1-9 heteroaryl group or a phenyl group (wherein the C1-9 heteroaryl group and the phenyl group are unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group, a cyano group, a C1-6 alkyl group, a trifluoromethyl group, a C1-6 alkoxy group, a sulfanyl group, a carbamoyl group, a (C1-6 acyl)amino group and an oxo group), and Y is NH.
9. A pyrazolopyrimidine compound represented by the formula III:
wherein
R1\u2032 represents a C1-6 alkyl group or a C3-8 cycloalkyl group (wherein the C1-8 alkyl group and the C3-8 cycloalkyl group are unsubstituted or substituted with 1 to 4 substituents selected from the following Substituent Group A\u2032);
Substituent Group A\u2032 represents
a group consisting of a halogen atom, a hydroxy group, an amino group, a cyano group, a carboxy group, a C1-6 alkyl group, a trifluoromethyl group, a C3-8 cycloalkyl group, a C1-6 alkoxy group (wherein the C1-6 alkoxy group is unsubstituted or substituted with a hydroxy group), a sulfanyl group, a C1-6 alkylsulfanyl group, a C1-6 alkoxycarbonyl group, a C3-8 cycloalkoxy group, a (C1-6 alkyl)amino group, a di(C1-6 alkyl)amino group, a C1-6 alkoxycarbonylamino group, a hydroxyaminocarbonyl group, a ureido group, a carbamoyl group, a C2-9 heterocyclyl group (wherein the C2-9 heterocyclyl group is unsubstituted or substituted with a C1-6 alkyl group or an oxo group), a C1-9 heteroaryl group, a (C1-6 acyl)amino group and an oxo group;
Y\u2032 represents \u2014O\u2014 or \u2014NR16\u2014 (wherein R16 represents a hydrogen atom or a C1-6 alkyl group);
Ar\u2032 represents a C1-9 heteroaryl group (wherein the C1-9 heteroaryl group is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of a sulfanyl group, a hydroxy group, a C1-6 alkoxy group, a morpholinyl group, a trifluoromethyl group and an oxo group) or a phenyl group (wherein the phenyl group is unsubstituted or substituted with the same or different 1 to 3 Rbs); and
Rb represents a hydroxy group, a cyano group, a carboxy group, a sulfanyl group, a C1-6 alkoxycarbonyl group, a C1-6 alkyl group (wherein the C1-6 alkyl group is unsubstituted or substituted with a carboxy group or \u2014CONR17R18 (wherein R17 and R18 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group)), a C3-8 cycloalkyl group, a C1-6 alkoxy group (wherein the C1-6 alkoxy group is unsubstituted or substituted with a carboxy group or \u2014CONR19R20 (wherein R19 and R20 are the same or different and each represent a hydrogen atom, a C1-6 alkyl group, a C3-8 cycloalkyl group, a C1-6 alkoxy group, a C2-9 heterocyclyl group or a C1-9 heteroaryl group)), a C1-9 heteroaryl group, a C3-8 cycloalkoxy group, a halogen atom, a trifluoromethyl group, a trifluoromethoxy group, a phenoxy group, a phenyl group (wherein the phenyl group is unsubstituted or substituted with a substituent selected from a carboxy group, a C1-6 alkoxycarbonyl group and \u2014SO2NR21R22 (wherein R21 and R22 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group)), \u2014NR23R24, \u2014CONR23R24, \u2014NR23SO2R24 or \u2014SO2NR23R24 (wherein R23 and R24 are the same or different and each represent a hydrogen atom, a C1-6 acyl group, a C1-6 alkoxycarbonyl group, a toluyl group, a naphthyl group, a C1-9 heteroaryl group or a C1-6 alkyl group (wherein the C1-6 alkyl group is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of a hydroxy group, a carboxy group and a C1-6 alkoxy group),
or when R23 and R24 are substituents on the adjacent nitrogen atom, they, together with the adjacent nitrogen atom, represent the formula IV:
wherein Q\u2032 represents \u2014O\u2014, \u2014NR25\u2014, \u2014CHR26\u2014, \u2014CO\u2014 (wherein the \u2014CO\u2014 is unprotected or protected with ethylene ketal), \u2014S\u2014, \u2014SO\u2014 or \u2014SO2\u2014;
L1 and L2\u2032 are the same or different and each represent a linear C1-3 alkylene group (wherein the linear C1-3 alkylene group is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of a C1-6 alkyl group and an oxo group);
R25 represents a hydrogen atom, a C1-6 acyl group, a C1-6 alkyl group, a C1-6 alkylsulfonyl group, a trifluoromethylsulfonyl group, a phenylcarbonyl group or a phenylsulfonyl group (wherein the phenylcarbonyl group and the phenylsulfonyl group are unsubstituted or substituted with 1 to 2 substituents selected from Substituent Group B\u2032);
Substituent Group B\u2032 represents a group consisting of a halogen atom, a C1-6 alkyl group and a C1-6 alkoxy group; and
R26 represents a hydrogen atom, a hydroxy group, a C1-6 alkyl group (wherein the C1-6 alkyl group is unsubstituted or substituted with a C1-6 alkoxy group or a hydroxy group), a C1-6 alkoxy group, a carboxy group, an amino group, a (C1-6 alkyl)amino group, a di(C1-6 alkyl)amino group, a (C1-6 acyl)amino group, a phenylcarbonyl group, \u2014CONR27R28 (wherein R27 and R28 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group, or they, together with the adjacent nitrogen atom, represent a C2-9 heterocyclyl group) or a (C1-6 alkylsulfonyl)amino group);
a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
10. The pyrazolopyrimidine compound, a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 9, wherein R1 is a C1-8 alkyl group (wherein the C1-6 alkyl group is unsubstituted or substituted with an amino group, a cyano group, a (C1-6 alkyl)amino group or a di(C1-6 alkyl)amino group).
11. The pyrazolopyrimidine compound, a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 9, wherein R1\u2032 is a C3-8 cycloalkyl group (wherein the C3-8 cycloalkyl group is unsubstituted or substituted with a hydroxy group or an amino group).
12. A Syk inhibitor comprising, as an active ingredient, the pyrazolopyrimidine compound, a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 1 or 2.
13. A therapeutic agent or prophylactic agent for allergic disease, autoimmune disease or arthritis, comprising, as an active ingredient, the pyrazolopyrimidine compound, a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 1 or 2.
14. An Abl inhibitor comprising, as an active ingredient, the pyrazolopyrimidine compound, a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 1 or 2.
15. A therapeutic agent or prophylactic agent for cancer, comprising, as an active ingredient, the pyrazolopyrimidine compound, a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 1 or 2.